Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer

Abstract

OBJECTIVE:This study sought to evaluate the prevalence of human papillomavirus (HPV) types 16 and 18 in women with clinical stage IB cervical cancer treated by radical hysterectomy with pelvic lymphadenectomy as well as to establish a correlation between HPV type and cancer prognosis.METHODS:A single-center cohort study was conducted with 86 patients who had undergone radical hysterectomy for stage I cervical cancer. Prognostic factors and the presence of HPV 16 and 18 were analyzed using a polymerase chain reaction assay. A univariate analysis using Kaplan-Meier curves was conducted to estimate survival.RESULTS:The prevalence of HPV 16 in the study group was 65.3%, and the prevalence of HPV 18 was 33.3%. The prevalence of infection with both viruses was 26.9%. Overall survival at 5 years was 91% among women with HPV 18 and 96% among those without this virus type (p = 0.133). Among the women with HPV 16, the overall survival was 94%, whereas this rate was 96% among those without this virus type (p = 0.663). Disease-free survival was unaffected by the presence of HPV type 16 or 18.CONCLUSION:In the present study, despite the high prevalence of HPV types 16 and 18, the presence of these virus types did not affect the prognosis of patients with stage I cervical cancer who underwent radical hysterectomy.

Independent prognostic role of human papillomavirus genotype in cervical cancer

“…In addition, HPV31-related and HPV58-related types were found to be associated with better survival outcome [7, 8]. However, no prognostic value of HPV type was reported by the other studies [9, 10]. The inconsistency may be attributed to the significant differences in sample size, length of follow-up, assay methods, and adjustment for known prognostic factors.…”

Significance of the Viral Load of High-risk Hpv in the Diagnosis and Prediction of Cervical Lesions: A Retrospective Study

“…High risk (HR)-HPV is the main cause of CC. HR-HPV subtypes such as HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, and 59 are closely associated (in decreasing oncogenic potential) with the occurrence of CC, and these associations are seen throughout the world [10], but there are some regional differences in the prevalence of the different HPV subtypes [11,12]. The HR-HPV viral load indicates the activity of HPV-DNA in the body [13,14].…”

“…The HR-HPV viral load indicates the activity of HPV-DNA in the body [13,14]. Studies showed that the type of HPV infection is closely related to the severity of cervical lesions and treatment prognosis [10][11][12], but there are inconsistent results from the studies on the correlation between the HPV viral load and the severity of cervical lesions [13][14][15][16][17][18][19]. At present, the correlation between the HPV viral load and cervical lesions has not been determined, and the signi cance of the HPV viral load in the detection and treatment of cervical lesions is still controversial [17,19].…”

Low Necroptosis Process Predicts Poor Treatment Outcome of Human Papillomavirus Positive Cervical Cancers by Decreasing Tumor-Associated Macrophages M1 Polarization

“…However, some studies showed that HPV DNA did not have any prognostic implication [8,9]. Furthermore, existing results on the relationship of HPV genotype with survival are also heterogeneous [4,10]. Therefore, identifying new molecular targets was needed to improve the prognosis and quality of life of patients with cervical cancer.…”

“…The major cause of invasive cervical cancer is persistent infection with high-risk human papillomavirus (HR-HPV). More than 170 genotypes have been described, and 2 HPV species, alpha-7 (HPV 18, 39, 45, 59, 68, and 70) and alpha-9 (HPV 16, 31, 33, 35, 52, 58, and 67), are classified as high-risk geno-DOI: 10.1159/000487434 types due to their high oncogenic potential [4]. Although there has been much evidence on the role of HPV in cervical precursor lesions and invasive cancer, it remains controversial how they affect prognosis of cervical cancer.…”